What bremelanotide actually is, and the receptor it shares with a tan

The melanocortin peptides keep coming up here because one branch of the family makes skin darker. Bremelanotide belongs to the same family and does something else entirely. It was pointed at the brain, approved for a condition that has nothing to do with pigment, and it still manages to darken skin as a side effect. The reason it can't quite avoid that is the whole story of what it is.

The family it comes from

Start with the shared ancestor. Your body cuts a hormone called alpha-MSH from a larger precursor, and that hormone lands on a set of five receptors, MC1R through MC5R, scattered across skin, brain, gut, and other tissues. MC1R sits on the pigment cells and is the one a tan runs through. The others do different jobs in different places. A melanocortin peptide is any molecule that binds this receptor family, and the interesting question for each one is always the same: which of the five does it hit, and where are those receptors.

Bremelanotide is a small cyclic peptide in this family, closely related to the gray-market tanning compounds. But its approved use points at MC4R, which is expressed on neurons throughout the central nervous system, not at the MC1R in your skin.

What it's approved for

The FDA approved bremelanotide in June 2019 under the name Vyleesi. The indication is narrow and specific: acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is a subcutaneous injection, taken as needed rather than daily, and it is a prescription drug with a label and a manufacturer, not a research chemical sold from an unregulated vial.

The approval rested on a pair of trials called RECONNECT, two identically designed, placebo-controlled studies running 24 weeks, across roughly 1,250 women. They measured two things: self-reported desire and the distress that low desire caused.

The "unknown" in its own label

Here is the part worth sitting with. For a drug that cleared the FDA, the prescribing information is unusually candid. It states plainly that the mechanism by which the drug improves the condition is not known. The reasoning is indirect: MC4R-bearing neurons are spread through the brain, bremelanotide activates MC4R, and so the effect is presumed to work through that pathway. Presumed, not shown.

That gap between "this receptor is involved" and "this is how the effect happens" is common in neuroscience and rarely stated so flatly on a label. It is a useful reminder that regulatory approval certifies a drug did something measurable in a trial. It does not certify that anyone fully understands why.

The receptor it couldn't miss

Bremelanotide is not clean. Its binding runs strongest at MC1R, then MC4R, then the rest, which means a peptide aimed at a brain receptor still lights up the one that controls pigment. The label reflects this. Focal darkening of the skin and gums shows up among the possible effects, more often with frequent dosing and in people with darker skin to begin with. The compound meant for the brain leaves a signature on the skin, through the same receptor the sun uses.

The rest of the side-effect profile is its own caution. Flushing was far more common on the drug than on placebo. Nausea is frequent. It can cause a temporary rise in blood pressure and a dip in heart rate, which is why the label rules it out for people with uncontrolled hypertension or known cardiovascular disease.

How to read the result

The honest summary is that the trials found a real, statistically significant effect, and that the effect was modest, enough that reviewers have argued for years about whether it clears the bar of being meaningful in a life rather than on a questionnaire. Both things are true at once. A difference can be genuine and small, and the interesting work is holding both halves of that without rounding either one away.

What bremelanotide illustrates best is that the melanocortin family is not one thing. The same lever, pulled on a different receptor in a different tissue, produces a different drug with a different file. One sibling darkens skin for a rare light disorder. One is sold as an unapproved tan. This one went to the brain, came back with a label and a long list of caveats, and still couldn't put down the receptor the rest of the family is named for.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.